| Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (NCT02335268) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2015-05-21 |
| National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup (NCT02192619) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2014-07-01 |
| Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines (NCT03622931) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2014-02-01 |
| PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood (NCT01509560) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2011-11-01 |
| SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment (NCT01418742) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2011-08-01 |
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP (NCT02983097) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-11-01 |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (NCT01243489) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-10-01 |
| Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment (NCT01320111) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-07-01 |
| Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (NCT01081431) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-03-26 |
| Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (NCT01090089) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-03-01 |
| Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma (NCT01019174) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2009-11-01 |
| Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma (NCT00891384) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2009-04-01 |